OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
EVFM
Evofem Biosciences, Inc.
0.0097
0.0004
4.30%
0.0096 / 0.0098 (1 x 1)
Evofem Biosciences, Inc.
7770 Regents Road
Suite 113-618
San Diego, CA 92122
12636 High Bluff Drive
Suite 400
San Diego, CA 92130
Since joining Evofem in 2018, Amy has progressively advanced to senior leadership roles, culminating in her appointment as Chief Business Development Officer in 2024. In this capacity, she successfully established the company's first ex-U.S. commercial agreement for PHEXXI (lactic acid, citric acid, and bitartrate), paving the way for the hormone-free contraceptive's entry into the UAE and other GCC markets. Additionally, she spearheaded Evofem's acquisition of SOLOSEC (secnidazole) 2g granules, an FDA-approved single-dose oral antibiotic for two common sexual health conditions. Amy is actively pursuing opportunities to enhance Evofem's growth strategy, focusing on potential acquisitions or licensing of additional assets in women's sexual and reproductive health, as well as partnerships to commercialize Evofem's products in international markets. With nearly 25 years of experience in both public and private healthcare companies, Amy has dedicated her career to advancing products that can significantly improve patients' lives. She holds a Bachelor of Arts from Smith College and Master of Fine Arts from Southern Methodist University.
None
600 California Street
Suite 600
San Francisco, CA 94108
525 B Street, Suite 2200
San Diego, CA 92101
Evofem currently derives revenue from two FDA-approved commercial products. PHEXXI is a hormone-free, on-demand prescription contraceptive vaginal gel indicated in the U.S. for pregnancy prevention. It is also approved in Nigeria. Regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico; filing is expected in the UAE in the first half of 2025 by our GCC commercial partner, Pharma 1. SOLOSEC provides a complete course of therapy to treat two common sexual health infections, bacterial vaginosis (BV) and trichomoniasis, with just one orally-administered dose.
We lease a corporate office in San Diego and are otherwise a virtual company. Manufacturing of PHEXXI and our product candidates is conducted by contractors at their facilities.
